Skip to Content

Join the 'Xeomin' group to help and get support from people like you.

Xeomin News

Forward-Thinking Tips for Back Pain

Posted 19 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 18, 2017 – Back pain is common but not inevitable, an orthopedist says. Roughly eight out of 10 people will suffer significant back pain at least once in their lifetime – but there are ways to reduce the risk, said Dr. Mark Knaub of Penn State Hershey Medical Center. Muscle, ligament or tendon strains (soft tissue injuries) are the most common causes of back pain. These injuries ...

Merz North America Announces FDA Approval of Xeomin (incobotulinumtoxinA) for Treatment of Adult Upper Limb Spasticity

Posted 30 Dec 2015 by Drugs.com

RALEIGH, N.C.- December 23, 2015 --Merz North America, U.S. affiliate of the global Merz Pharma Group, announces that Xeomin (incobotulinumtoxinA) has received U.S. FDA approval for the treatment of upper limb spasticity (ULS) in adult patients. In clinical studies, treatment with Xeomin (incobotulinumtoxinA) for adult ULS resulted in statistically and clinically significant improvements in ...

Medication Errors Occur Every 8 Minutes in U.S. Children

Posted 20 Oct 2014 by Drugs.com

MONDAY, Oct. 20, 2014 – A child receives the wrong medication or the wrong dosage every eight minutes in the United States, according to a recent study. Nearly 700,000 children under 6 years old experienced an out-of-hospital medication error between 2002 and 2012. Out of those episodes, one out of four children was under a year old. As the age of children decreased, the likelihood of an error ...

Accidental Medication Poisonings in Kids on the Rise

Posted 16 Sep 2011 by Drugs.com

FRIDAY, Sept. 16 – Despite ongoing prevention efforts, a growing number of young children are being accidentally poisoned with medications, according to new research. The study, which was based on data reported to the American Association of Poison Control Centers between 2001 and 2008, found that medication poisoning among children aged 5 and under increased by 22 percent, although the number ...

Merz Aesthetics Announces FDA Approval Of Xeomin (incobotulinumtoxinA) For The Temporary Improvement In The Appearance Of Moderate To Severe Glabellar Lines In Adult Patients

Posted 21 Jul 2011 by Drugs.com

SAN MATEO, Calif., July 21, 2011 /PRNewswire/ – Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients. "The FDA approval of Xeomin is a significant milestone for Merz ...

Ask a Question

Further Information

Related Condition Support Groups

Facial Wrinkles, Blepharospasm, Upper Limb Spasticity, Cervical Dystonia

Xeomin Patient Information at Drugs.com